Added: Karli Swank - Date: 21.02.2022 18:37 - Views: 21303 - Clicks: 6772
DOI: Abstract Disclosures. Background: Older adults with multiple comorbidities and poor functional status may not be appropriate candidates for chemotherapy. We conducted a phase II trial to examine the safety and efficacy of single-agent Trastuzumab for older women with early stage Human Epidermal Growth Factor Receptor Type 2 Her2 -positive breast cancer. The primary end point was one-year cumulative incidence of symptomatic congestive heart failure with reduced ejection fraction HFrEF.
: Fifty-six patients were enrolled across four centers with a median follow-up period of 5. The median age was Only two patients had symptomatic congestive HFrEF with a one-year cumulative incidence of 3. Five patients had asymptomatic declines in ejection fraction with a one-year cumulative incidence of 9. The 5-year DFS was Among seven relapses seen, two were due to distant metastatic breast cancer. The 5-year rate of overall survival was Among five deaths, one was due to distant metastatic breast cancer. Conclusions: Among older women with stage I-III HER2-positive breast cancer who decline chemotherapy or are not chemotherapy candidates, treatment with her2 targeted therapy only without chemotherapy may offer a reasonable treatment option without an inordinate rate of cardiac toxicity.
Clinical trial information: NCT Article Tools. Safety and efficacy of single-agent adjuvant trastuzumab in older women with early-stage breast cancer.
Cynthia Owusu x Cynthia Owusu. Search for articles by this author. Abstract Abstract. Keywords: 4 3 3 2 2 6.
Published online May 25, Export Citation. Track Citation. Add To Favorites.Mature single lady Salem al
email: [email protected] - phone:(809) 758-2855 x 4504
How the Flag Came to be Called Old Glory